Pfizer Inc. (PFE) Clears U.S. Antitrust Review for Acquisition of All Outstanding Shares of Encysive Pharmaceuticals (ENCY)  
3/27/2008 8:46:06 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) has expired in connection with the tender offer by its wholly-owned subsidiary, Explorer Acquisition Corp., to purchase all of the outstanding shares of common stock of Encysive Pharmaceuticals Inc. (NASDAQ: ENCY) at a purchase price of $2.35 per share, net to the seller in cash, without interest thereon and less any required withholding taxes.